James Andrew McCubrey

List of Publications by Year in Descending Order

335 papers	16,846 citations	62 h-index	117 g-index
348 ext. papers	18,714 ext. citations	5.3 avg, IF	6.32 L-index

#	Paper	IF	Citations
335	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.. *Cells*, **2022**, 11,	7.9	1
334	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.. *Aging*, **2022**, 14, 3365-3386	5.6	0
333	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. *Cells*, **2022**, 11, 1812	7.9	1
332	The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. *Drug Discovery Today*, **2021**,	8.8	5
331	Role of PLC in the modulation of cell migration and cell invasion in glioblastoma. *Advances in Biological Regulation*, **2021**, 100838	6.2	1
330	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. *Advances in Biological Regulation*, **2021**, 100840	6.2	0
329	Recent Progress in Discovering the Role of Carotenoids and Their Metabolites in Prostatic Physiology and Pathology with a Focus on Prostate Cancer-A Review-Part I: Molecular Mechanisms of Carotenoid Action. *Antioxidants*, **2021**, 10,	7.1	5
328	GSK-3 Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. *Cells*, **2021**, 10,	7.9	7
327	GSK-3: a multifaceted player in acute leukemias. *Leukemia*, **2021**, 35, 1829-1842	10.7	4
326	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. *Advances in Biological Regulation*, **2021**, 79, 100780	6.2	3
325	Recent Progress in Discovering the Role of Carotenoids and Metabolites in Prostatic Physiology and Pathology-A Review-Part II: Carotenoids in the Human Studies. *Antioxidants*, **2021**, 10,	7.1	10
324	GSK3 as a Regulator of Cytoskeleton Architecture: Consequences for Health and Disease. *Cells*, **2021**, 10,	7.9	3
323	Lamin B1 Accumulation Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. *Cells*, **2021**, 10,	7.9	1
322	The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. *Cancer Letters* , **2021**, 519, 250-262	9.9	2
321	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. *Advances in Biological Regulation*, **2021**, 79, 100771	6.2	4
320	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. *Cells*, **2020**, 9,	7.9	67
319	The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. *Cells*, **2020**, 9,	7.9	16

318	GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118770	4.9	5
317	Where are we with understanding of COVID-19?. *Advances in Biological Regulation*, **2020**, 78, 100738	6.2	3
316	GSK3 and miRNA in neural tissue: From brain development to neurodegenerative diseases. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118696	4.9	4
315	GSK-3-associated signaling is crucial to virus infection of cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118767	4.9	4
314	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. *Cancers*, **2020**, 12,	6.6	17
313	The Reverse Warburg Effect is Associated with Fbp2-Dependent Hif1 Regulation in Cancer Cells Stimulated by Fibroblasts. *Cells*, **2020**, 9,	7.9	8
312	TP53/miR-34a-associated signaling targets expression in human pancreatic cancer. *Aging*, **2020**, 12, 2777-2797	5.6	11
311	New landscapes and horizons in hepatocellular carcinoma therapy. *Aging*, **2020**, 12, 3053-3094	5.6	23
310	Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure. *Aging*, **2020**, 12, 3388-3406	5.6	7
309	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. *Aging*, **2020**, 12, 10194-10210	5.6	11
308	GSK-3 in liver diseases: Friend or foe?. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118743	4.9	1
307	Recent advances in MDS mutation landscape: Splicing and signalling. *Advances in Biological Regulation*, **2020**, 75, 100673	6.2	4
306	Abilities of Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. *Advances in Biological Regulation*, **2020**, 75, 100672	6.2	7
305	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. *Advances in Biological Regulation*, **2020**, 78, 100758	6.2	9
304	Where are we with understanding of COVID-19?. *Advances in Biological Regulation*, **2020**, 77, 100745	6.2	1
303	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
302	Cancer therapy and treatments during COVID-19 era. *Advances in Biological Regulation*, **2020**, 77, 100739	6.2	19
301	Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). *FASEB Journal*, **2020**, 34, 15400-15416	8.9	1

300	Inositide-Dependent Nuclear Signalling in Health and Disease. *Handbook of Experimental Pharmacology*, **2020**, 259, 291-308	3.2	2
299	Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. *Pharmaceuticals*, **2019**, 12,	5.2	5
298	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. *Cancers*, **2019**, 11,	6.6	17
297	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. *Advances in Biological Regulation*, **2019**, 73, 100633	6.2	15
296	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2019**, 1866, 1322-1337	4.9	10
295	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. *Advances in Biological Regulation*, **2019**, 72, 22-40	6.2	7
294	miRNAs and their roles in KSHV pathogenesis. *Virus Research*, **2019**, 266, 15-24	6.4	9
293	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. *Leukemia*, **2019**, 33, 2276-2290	10.7	17
292	RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. *Expert Opinion on Therapeutic Targets*, **2019**, 23, 915-929	6.4	26
291	Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. *Journal of Cellular Physiology*, **2019**, 234, 11188-11199	7	14
290	Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. *Advances in Biological Regulation*, **2019**, 71, 1-9	6.2	12
289	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. *Advances in Biological Regulation*, **2019**, 71, 172-182	6.2	25
288	Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. *International Journal of Cancer*, **2019**, 144, 2613-2624	7.5	22
287	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. *Journal of Lipid Research*, **2019**, 60, 312-317	6.3	16
286	Metformin influences drug sensitivity in pancreatic cancer cells. *Advances in Biological Regulation*, **2018**, 68, 13-30	6.2	34
285	Drug discovery targeting the mTOR pathway. *Clinical Science*, **2018**, 132, 543-568	6.5	46
284	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. *Journal of Cellular Physiology*, **2018**, 233, 6440-6454	7	23
283	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. *Expert Review of Precision Medicine and Drug Development*, **2018**, 3, 23-31	1.6	1

282	Cutaneous melanoma: From pathogenesis to therapy (Review). *International Journal of Oncology*, **2018**, 52, 1071-1080	4.4	164
281	Nuclear translocation of PKC-δ is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). *FASEB Journal*, **2018**, 32, 681-692	0.9	16
280	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. *Advances in Biological Regulation*, **2018**, 67, 190-211	6.2	21
279	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	24
278	Roles of p53, NF-ΒB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. *Advances in Biological Regulation*, **2018**, 69, 43-62	6.2	16
277	Nuclear Nox4 interaction with prelamin A is associated with nuclear redox control of stem cell aging. *Aging*, **2018**, 10, 2911-2934	5.6	19
276	Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. *Oncotarget*, **2018**, 9, 17220-17237	3.3	26
275	Nuclear inositide signaling and cell cycle. *Advances in Biological Regulation*, **2018**, 67, 1-6	6.2	25
274	Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. *Oncotarget*, **2018**, 9, 17238-17254	3.3	35
273	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 833-848	6.4	52
272	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. *Oncotarget*, **2018**, 9, 14005-14034	3.3	46
271	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. *Breast Cancer Research*, **2018**, 20, 105	8.3	38
270	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. *Oncotarget*, **2018**, 9, 8263-8277	3.3	54
269	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. *Advances in Biological Regulation*, **2018**, 69, 16-34	6.2	20
268	Nuclear Inositide Signaling Via Phospholipase C. *Journal of Cellular Biochemistry*, **2017**, 118, 1969-1978	4.7	22
267	PLC-δ1 and cell differentiation: An insight into myogenesis and osteogenesis. *Advances in Biological Regulation*, **2017**, 63, 1-5	6.2	27
266	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. *Scientific Reports*, **2017**, 7, 43013	4.9	36
265	Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. *Advances in Biological Regulation*, **2017**, 65, 59-76	6.2	27

264	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. *Advances in Biological Regulation*, **2017**, 65, 77-88	6.2	31
263	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. *Oncotarget*, **2017**, 8, 91803-91816	3.3	17
262	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. *Aging*, **2017**, 9, 1477-1536	5.6	112
261	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. *Oncotarget*, **2017**, 8, 14221-14250	3.3	68
260	HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. *International Journal of Cancer*, **2017**, 140, 1713-1726	7.5	53
259	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. *Advances in Biological Regulation*, **2017**, 63, 32-48	6.2	28
258	Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell. *Oncotarget*, **2017**, 8, 115420-115433	3.3	10
257	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. *Oncotarget*, **2017**, 8, 23213-23227	3.3	10
256	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. *Oncotarget*, **2017**, 8, 76525-76557	3.3	15
255	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. *Oncotarget*, **2017**, 8, 113013-113033	3.3	8
254	Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation. *International Journal of Oncology*, **2017**, 51, 533-544	4.4	56
253	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 449-463	4.9	81
252	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 438-448	4.9	56
251	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. *Journal of Cellular Physiology*, **2016**, 231, 1645-55	7	24
250	The therapeutic potential of mTOR inhibitors in breast cancer. *British Journal of Clinical Pharmacology*, **2016**, 82, 1189-1212	3.8	72
249	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. *Tumor Biology*, **2016**, 37, 9855-63	2.9	12
248	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 483-489	4.9	22
247	A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. *Cell Cycle*, **2016**, 15, 573-83	4.7	21

246	Modulation of nuclear PI-PLCbeta1 during cell differentiation. *Advances in Biological Regulation*, **2016**, 60, 1-5	6.2	19
245	Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 677-87	6.4	12
244	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. *Advances in Biological Regulation*, **2016**, 60, 64-87	6.2	26
243	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. *Oncotarget*, **2016**, 7, 55690-55703	3.3	11
242	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. *Oncotarget*, **2016**, 7, 72758-72766	3.3	65
241	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. *Oncotarget*, **2016**, 7, 79842-79853	3.3	17
240	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-B. *Oncotarget*, **2016**, 7, 1323-40	3.3	30
239	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. *Current Pharmaceutical Design*, **2016**, 22, 2345-8	3.3	18
238	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. *Current Pharmaceutical Design*, **2016**, 22, 2358-88	3.3	30
237	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. *PLoS ONE*, **2016**, 11, e0152104	3.7	37
236	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. *Aging*, **2016**, 8, 933-44	5.6	57
235	Effects of mutations in Wnt/-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2016**, 1863, 2942-2976	4.9	101
234	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. *Advances in Biological Regulation*, **2015**, 59, 65-81	6.2	98
233	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. *Leukemia Research*, **2015**, 39, 1088-95	2.7	24
232	PLC and PI3K/Akt/mTOR signalling in disease and cancer. *Advances in Biological Regulation*, **2015**, 57, 10-6	6.2	95
231	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. *Advances in Biological Regulation*, **2015**, 57, 75-101	6.2	76
230	Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2015**, 1853, 14-26	4.9	58
229	Raf/MEK/ERK Signaling **2015**, 275-305		

228	Malignant melanoma in elderly patients: biological, surgical and medical issues. *Expert Review of Anticancer Therapy*, **2015**, 15, 101-8	3.5	26
227	Current treatment strategies for inhibiting mTOR in cancer. *Trends in Pharmacological Sciences*, **2015**, 36, 124-35	13.2	195
226	Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. *Oncotarget*, **2015**, 6, 1707-22	3.3	21
225	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. *Oncotarget*, **2015**, 6, 6597-610	3.3	23
224	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. *Oncotarget*, **2015**, 6, 10399-414	3.3	29
223	Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood. *Oncotarget*, **2015**, 6, 10924-39	3.3	6
222	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. *Oncotarget*, **2015**, 6, 17147-60	3.3	28
221	Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. *Oncotarget*, **2015**, 6, 17237-50	3.3	7
220	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. *Oncotarget*, **2015**, 6, 32089-103	3.3	30
219	Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. *Advances in Biological Regulation*, **2014**, 54, 176-96	6.2	64
218	Foreword: "Targeting signaling pathways in stem cells". *Advances in Biological Regulation*, **2014**, 56, 1-5	6.2	4
217	Nuclear PI-PLC□1: an appraisal on targets and pathology. *Advances in Biological Regulation*, **2014**, 54, 2-11	6.2	28
216	Targeting breast cancer initiating cells: advances in breast cancer research and therapy. *Advances in Biological Regulation*, **2014**, 56, 81-107	6.2	28
215	NOTCH and PTEN in prostate cancer. *Advances in Biological Regulation*, **2014**, 56, 51-65	6.2	39
214	Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. *Advances in Biological Regulation*, **2014**, 56, 45-50	6.2	73
213	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). *International Journal of Oncology*, **2014**, 45, 909-18	4.4	19
212	Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure. *Oncology Reports*, **2014**, 31, 1079-82	3.5	37
211	Emerging targeted therapies for melanoma treatment (review). *International Journal of Oncology*, **2014**, 45, 516-24	4.4	37

210	Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24?/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. *International Journal of Oncology*, **2014**, 45, 1193-9	4.4	35
209	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. *Oncotarget*, **2014**, 5, 1576-94	3.3	70
208	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. *Oncotarget*, **2014**, 5, 4603-50	3.3	179
207	GSK-3 as potential target for therapeutic intervention in cancer. *Oncotarget*, **2014**, 5, 2881-911	3.3	332
206	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. *Cell Cycle*, **2014**, 13, 2237-47	4.7	28
205	Inhibition of GSK-3 activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. *Cell Cycle*, **2014**, 13, 820-33	4.7	36
204	Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ER expression in initially ER breast cancer cells. *PLoS ONE*, **2014**, 9, e96995	3.7	23
203	PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. *Oncotarget*, **2014**, 5, 4222-31	3.3	18
202	Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. *Oncotarget*, **2014**, 5, 7886-901	3.3	30
201	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. *Oncotarget*, **2014**, 5, 10034-47	3.3	44
200	A novel DAG-dependent mechanism links PKC? and Cyclin B1 regulating cell cycle progression. *Oncotarget*, **2014**, 5, 11526-40	3.3	16
199	Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. *Current Pharmaceutical Design*, **2014**, 20, 3944-57	3.3	42
198	Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. *Basic and Clinical Pharmacology and Toxicology*, **2013**, 112, 63-9	3.1	14
197	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways **2013**, 331-372		1
196	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. *Advances in Biological Regulation*, **2013**, 53, 146-55	6.2	14
195	K562 cell proliferation is modulated by PLC through a PKC-mediated pathway. *Cell Cycle*, **2013**, 12, 1713-21	4.7	23
194	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. *Expert Opinion on Therapeutic Targets*, **2013**, 17, 921-36	6.4	11
193	Nuclear phospholipase C signaling, epigenetics and treatments in MDS. *Advances in Biological Regulation*, **2013**, 53, 2-7	6.2	29

192	Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. *Oncology Reports*, **2013**, 29, 1785-8	3.5	16
191	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIVOSTI NA DOKSORUBICIN. *Journal of Medical Biochemistry*, **2013**, 32, 406-416	1.9	1
190	Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. *PLoS ONE*, **2013**, 8, e65569	3.7	25
189	The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. *Oncotarget*, **2013**, 4, 1496-506	3.3	47
188	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review). *Molecular Medicine Reports*, **2012**, 6, 687-94	2.9	20
187	Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. *International Journal of Oncology*, **2012**, 40, 1858-64	4.4	21
186	Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. *Molecular Pharmacology*, **2012**, 82, 700-10	4.3	24
185	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. *Journal of Molecular Medicine*, **2012**, 90, 1133-44	5.5	34
184	Novel approaches to target cancer initiating cells-eliminating the root of the cancer. *Advances in Biological Regulation*, **2012**, 52, 249-64	6.2	13
183	Revisiting nuclear phospholipase C signalling in MDS. *Advances in Biological Regulation*, **2012**, 52, 2-6	6.2	20
182	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. *Advances in Biological Regulation*, **2012**, 52, 214-27	6.2	18
181	The novel NF-B inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. *Cancer Letters*, **2012**, 322, 35-44	9.9	30
180	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 729-42	6.4	34
179	Targeting the cancer initiating cell: the ultimate target for cancer therapy. *Current Pharmaceutical Design*, **2012**, 18, 1784-95	3.3	36
178	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget*, **2012**, 3, 1068-111	3.3	250
177	Recent discoveries in the cycling, growing and aging of the p53 field. *Aging*, **2012**, 4, 887-93	5.6	18
176	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget*, **2012**, 3, 954-87	3.3	214
175	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. *Oncotarget*, **2012**, 3, 236-60	3.3	138

174	Molecular mechanisms of sorafenib action in liver cancer cells. *Cell Cycle*, **2012**, 11, 2843-55	4.7	106
173	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. *Journal of Molecular Medicine*, **2012**, 90, 667-79	5.5	46
172	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). *International Journal of Oncology*, **2012**, 40, 639-44	4.4	71
171	Activity of the selective IB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. *Cell Cycle*, **2012**, 11, 2467-75	4.7	32
170	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. *Cell Cycle*, **2012**, 11, 1174-82	4.7	12
169	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. *Cell Cycle*, **2012**, 11, 4579-88	4.7	73
168	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. *Cell Cycle*, **2012**, 11, 4447-61	4.7	21
167	Nuclear PI-PLC and myelodysplastic syndromes: genetics and epigenetics. *Current Pharmaceutical Design*, **2012**, 18, 1751-4	3.3	8
166	Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. *Current Drug Delivery*, **2012**, 9, 17-29	3.2	21
165	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. *Oncotarget*, **2012**, 3, 371-94	3.3	98
164	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. *Oncotarget*, **2012**, 3, 811-23	3.3	53
163	Effects of ectopic expression of NGAL on doxorubicin sensitivity. *Oncotarget*, **2012**, 3, 1236-45	3.3	13
162	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. *Oncotarget*, **2012**, 3, 1615-28	3.3	51
161	Advances in targeting signal transduction pathways. *Oncotarget*, **2012**, 3, 1505-21	3.3	39
160	Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. *Oncotarget*, **2012**, 3, 1522-32	3.3	21
159	The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). *Advances in Enzyme Regulation*, **2011**, 51, 195-207		38
158	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. *Cell Cycle*, **2011**, 10, 492-9	4.7	36
157	mTOR as a multifunctional therapeutic target in HIV infection. *Drug Discovery Today*, **2011**, 16, 715-21	8.8	84

156	Targeting the cancer initiating cell: the AchillesPheel of cancer. *Advances in Enzyme Regulation*, **2011**, 51, 152-62		13
155	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2011**, 226, 822-31	7	52
154	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. *Journal of Cellular Physiology*, **2011**, 226, 2762-81	7	124
153	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. *Cell Cycle*, **2011**, 10, 3003-15	4.7	71
152	COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. *OMICS A Journal of Integrative Biology*, **2011**, 15, 383-92	3.8	26
151	Characterization of human melanoma cell lines and melanocytes by proteome analysis. *Cell Cycle*, **2011**, 10, 2924-36	4.7	25
150	Nuclear phosphoinositides and their roles in cell biology and disease. *Critical Reviews in Biochemistry and Molecular Biology*, **2011**, 46, 436-57	8.7	28
149	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. *Aging*, **2011**, 3, 192-222	5.6	437
148	Recent progress in targeting cancer. *Aging*, **2011**, 3, 1154-62	5.6	9
147	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget*, **2011**, 2, 135-64	3.3	456
146	Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. *Oncotarget*, **2011**, 2, 109-12	3.3	17
145	Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. *Oncotarget*, **2011**, 2, 538-50	3.3	69
144	Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. *Oncotarget*, **2011**, 2, 610-26	3.3	38
143	Potential use of rapamycin in HIV infection. *British Journal of Clinical Pharmacology*, **2010**, 70, 784-93	3.8	56
142	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. *Cancer Research*, **2010**, 70, 8097-107	10.1	136
141	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. *Cell Cycle*, **2010**, 9, 1781-91	4.7	97
140	The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. *Cancers*, **2010**, 2, 1576-96	6.6	32
139	Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. *Cell Cycle*, **2010**, 9, 1629-38	4.7	36

138	Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. *Cell Cycle*, **2010**, 9, 1839-46	4.7	27
137	Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. *Cell Cycle*, **2010**, 9, 384-8	4.7	24
136	Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. *Cell Cycle*, **2010**, 9, 1399-410	4.7	37
135	Emerging MEK inhibitors. *Expert Opinion on Emerging Drugs*, **2010**, 15, 203-23	3.7	50
134	New perspectives in HCV therapy: entry inhibitors. *Recent Patents on Anti-infective Drug Discovery*, **2010**, 5, 181-94	1.6	2
133	Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. *Advances in Enzyme Regulation*, **2010**, 50, 285-307		38
132	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2010**, 1803, 991-1002	4.9	97
131	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. *Free Radical Biology and Medicine*, **2010**, 48, 1090-9	7.8	10
130	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. *Histology and Histopathology*, **2010**, 25, 669-80	1.4	29
129	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. *Oncotarget*, **2010**, 1, 89-103	3.3	200
128	Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. *Molecular Pharmacology*, **2009**, 76, 290-300	4.3	43
127	Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. *Cancer Research*, **2009**, 69, 3520-8	10.1	106
126	The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers. *Cell Cycle*, **2009**, 8, 1421-5	4.7	8
125	The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate activity in cancer cells. *Current Cancer Drug Targets*, **2009**, 9, 72-80	2.8	36
124	Emerging Raf inhibitors. *Expert Opinion on Emerging Drugs*, **2009**, 14, 633-48	3.7	30
123	PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. *Cell Cycle*, **2009**, 8, 1352-8	4.7	133
122	Melanoma: molecular pathogenesis and emerging target therapies (Review). *International Journal of Oncology*, **2009**, 34, 1481-9	1	51
121	Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. *Prostate*, **2009**, 69, 1448-59	4.2	62

120	The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. *Molecular Cancer Therapeutics*, **2009**, 8, 1169-78	6.1	33
119	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. *Expert Opinion on Investigational Drugs*, **2009**, 18, 1333-49	5.9	94
118	Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments. *Current Signal Transduction Therapy*, **2009**, 4, 130-143	0.8	10
117	Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. *Blood*, **2009**, 114, 594-594	2.2	
116	Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.. *Blood*, **2009**, 114, 2757-2757	2.2	
115	Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.. *Blood*, **2009**, 114, 2025-2025	2.2	
114	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. *Leukemia*, **2008**, 22, 2080-90	10.7	59
113	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. *Leukemia*, **2008**, 22, 708-22	10.7	194
112	Senescence-associated exosome release from human prostate cancer cells. *Cancer Research*, **2008**, 68, 7864-71	10.1	310
111	Akt as a therapeutic target in cancer. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 1139-65	6.4	114
110	Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. *Cancer Research*, **2008**, 68, 9394-403	10.1	76
109	Targeting prostate cancer based on signal transduction and cell cycle pathways. *Cell Cycle*, **2008**, 7, 1745-62	4.7	80
108	Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of BCL2 overexpressing immortalized breast cell line. *Cell Cycle*, **2008**, 7, 3062-73	4.7	3
107	Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. *Cell Cycle*, **2008**, 7, 631-6	4.7	30
106	PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. *Journal of Biological Chemistry*, **2008**, 283, 35474-85	5.4	39
105	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. *Molecular Pharmacology*, **2008**, 74, 884-95	4.3	31
104	GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. *Cancer Biology and Therapy*, **2008**, 7, 1079	4.6	8
103	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). *Molecular Medicine Reports*, **2008**,	2.9	2

102	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. *Advances in Enzyme Regulation*, **2008**, 48, 113-35		20
101	PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia.. *Blood*, **2008**, 112, 1921-1921	2.2	1
100	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy **2008**, 81-114		
99	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. *Blood*, **2008**, 112, 957-957	2.2	
98	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells. *Blood*, **2008**, 112, 503-503	2.2	
97	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). *Blood*, **2008**, 112, 860-860	2.2	1
96	The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation. *Blood*, **2008**, 112, 4489-4489	2.2	
95	Erucylphosphohomocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.. *Blood*, **2008**, 112, 1330-1330	2.2	
94	Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. *Current Opinion in Investigational Drugs*, **2008**, 9, 614-30		50
93	PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. *BMC Cancer*, **2007**, 7, 137	4.8	34
92	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2007**, 1773, 1263-84	4.9	1532
91	Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. *Advances in Enzyme Regulation*, **2007**, 47, 64-103		63
90	Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 589-99	6.4	18
89	A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. *Cell Cycle*, **2007**, 6, 595-605	4.7	80
88	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. *Cancer Biology and Therapy*, **2007**, 6, 1165-70	4.6	12
87	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. *Drug Resistance Updates*, **2007**, 10, 81-100	23.2	62
86	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. *Blood*, **2007**, 110, 3470-3470	2.2	1
85	The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. *Blood*, **2007**, 110, 3355-3355	2.2	

84	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. *Blood*, **2007**, 110, 3344-3344	2.2	1
83	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. *Blood*, **2007**, 110, 641-641	2.2	
82	Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.. *Blood*, **2007**, 110, 875-875	2.2	
81	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance **2006**, 101-134		2
80	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. *Cancer Cell*, **2006**, 10, 375-88	24.3	820
79	Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. *Journal of Clinical Laboratory Analysis*, **2006**, 20, 173-6	3	20
78	Detection of BRAF gene mutation in primary choroidal melanoma tissue. *Cancer Biology and Therapy*, **2006**, 5, 225-7	4.6	32
77	EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. *Cell Cycle* , **2006**, 5, 2820-6	4.7	56
76	Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. *Cancer Biology and Therapy*, **2006**, 5, 1022-30	4.6	25
75	OSU-03012 in the treatment of glioblastoma. *Molecular Pharmacology*, **2006**, 70, 437-9	4.3	15
74	Absence of BRAF gene mutation in non-melanoma skin tumors. *Cell Cycle*, **2006**, 5, 968-70	4.7	22
73	Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. *Antioxidants and Redox Signaling*, **2006**, 8, 1807-17	8.4	36
72	Reactive oxygen species-induced activation of the MAP kinase signaling pathways. *Antioxidants and Redox Signaling*, **2006**, 8, 1775-89	8.4	588
71	Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. *Antioxidants and Redox Signaling*, **2006**, 8, 1749-56	8.4	39
70	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. *Advances in Enzyme Regulation*, **2006**, 46, 249-79		518
69	Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.. *Blood*, **2006**, 108, 1455-1455	2.2	
68	Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.. *Blood*, **2006**, 108, 1116-1116	2.2	
67	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells **2005**, 26, 1637		0

66	Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. *Cell Cycle*, **2005**, 4, 818-21	4.7	9
65	Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. *Cell Cycle*, **2005**, 4, 483-7	4.7	7
64	Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. *Cell Cycle*, **2005**, 4, 1389-95	4.7	40
63	Analysis of BRAF mutation in primary and metastatic melanoma. *Cell Cycle*, **2005**, 4, 1382-4	4.7	78
62	Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. *Expert Opinion on Therapeutic Targets*, **2005**, 9, 791-808	6.4	27
61	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what? genetics got to do with it?. *Expert Opinion on Therapeutic Targets*, **2005**, 9, 1009-30	6.4	45
60	Cigarette smoke concentrate inhibits Kaposi? sarcoma-associated herpesvirus infection. *Virus Research*, **2005**, 114, 172-6	6.4	9
59	A novel ring-substituted diindolylmethane,1,1-bis[3?(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. *Cancer Research*, **2005**, 65, 2890-8	10.1	105
58	B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. *Blood*, **2005**, 105, 4516-22	2.2	44
57	Inhibition of CREB transcriptional activity in human T lymphocytes by oxidative stress. *Free Radical Biology and Medicine*, **2005**, 38, 1653-61	7.8	10
56	Biology of Kaposi? sarcoma-associated herpesvirus. *Frontiers in Bioscience - Landmark*, **2005**, 10, 2882-91	2.8	10
55	Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. *Cancer Research*, **2005**, 65, 9962-70	10.1	16
54	Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. *Cancer Research*, **2005**, 65, 9164-8	10.1	42
53	Solubility and bioactivity of the Pseudomonas quinolone signal are increased by a Pseudomonas aeruginosa-produced surfactant. *Infection and Immunity*, **2005**, 73, 878-82	3.7	73
52	Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. *Cancer Research*, **2005**, 65, 5408-16	10.1	60
51	Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. *Cancer Research*, **2005**, 65, 4401-7	10.1	20
50	Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. *Cancer Biology and Therapy*, **2005**, 4, 1192-4	4.6	25
49	Upping the bid on engineered inducible cell death. *Cancer Biology and Therapy*, **2005**, 4, 537	4.6	

48	Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. *Cell Cycle*, **2005**, 4, 822-30	4.7	25
47	Key Roles of the Raf-1 and Akt in Drug Resistance, Cell Cycle Progression and the Prevention of Apoptosis in Hematopoietic Cells.. *Blood*, **2005**, 106, 1356-1356	2.2	
46	Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway.. *Blood*, **2005**, 106, 4291-4291	2.2	
45	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. *International Journal of Oncology*, **2005**, 26, 1637-44	1	12
44	Pharmacological breast cancer therapy (review). *International Journal of Oncology*, **2005**, 27, 1341-4	1	7
43	Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells. *Cell Cycle*, **2004**, 3, 370-377	4.7	29
42	Signaling through 3′,5′cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5196-203	5.6	23
41	Raf-induced vascular endothelial growth factor augments Kaposiβ sarcoma-associated herpesvirus infection. *Journal of Virology*, **2004**, 78, 13381-90	6.6	24
40	Phosphatidylinositol 3′kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. *Cancer Research*, **2004**, 64, 8397-404	10.1	146
39	Role for Raf in the entry of viruses associated with AIDS (Review) **2004**, 25, 469		1
38	B-Raf and Insulin Synergistically Prevent Apoptosis and Induce Cell Cycle Progression in Hematopoietic Cell. *Cell Cycle*, **2004**, 3, 184-191	4.7	3
37	Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. *Cancer Biology and Therapy*, **2004**, 3, 876-81	4.6	22
36	Redox regulation of the calcium/calmodulin-dependent protein kinases. *Journal of Biological Chemistry*, **2004**, 279, 44573-81	5.4	105
35	The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. *Expert Opinion on Therapeutic Targets*, **2004**, 8, 537-50	6.4	77
34	Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. *Oncogene*, **2004**, 23, 5227-41	9.2	36
33	Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. *Oncogene*, **2004**, 23, 8659-72	9.2	44
32	Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. *Oncogene*, **2004**, 23, 7810-20	9.2	19
31	Ability of the Activated PI3K/Akt Oncoproteins to Synergize with MEK1 and Induce Cell Cycle Progression and Abrogate the Cytokine-Dependence of Hematopoietic Cells. *Cell Cycle*, **2004**, 3, 501-510	4.7	11

30	A Novel Ring-Substituted Diindolylmethane 1,1-bis [3?-(5-methoxyindolyl)]-1-(p-t-butylphenyl) Methane Abrogates ERK Activation and Induces Apoptosis in Acute Myeloid Leukemia (AML).. *Blood* , **2004**, 104, 3399-3399	2.2	
29	B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. *Cell Cycle*, **2004**, 3, 189-96	4.7	7
28	Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. *Cell Cycle*, **2004**, 3, 503-12	4.7	19
27	Models of anergy in the human Jurkat T cell line. *Assay and Drug Development Technologies*, **2003**, 1, 537-44	2.1	8
26	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review) **2003**, 22, 237		11
25	Docetaxel Cytotoxicity is Enhanced by Inhibition of the Raf/MEK/ERK Signal Transduction Pathway. *Cancer Biology and Therapy*, **2003**, 2, 676-677	4.6	9
24	Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. *Oncogene*, **2003**, 22, 2478-92	9.2	92
23	Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer. *Methods in Molecular Biology*, **2003**, 218, 185-201	1.4	
22	Elucidation of signal transduction pathways by transfection of cells with modified oncogenes. *Methods in Molecular Biology*, **2003**, 218, 203-20	1.4	
21	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). *International Journal of Oncology*, **2003**, 22, 237-52	1	59
20	Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). *International Journal of Oncology*, **2003**, 22, 469-80	1	113
19	Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. *Clinical Cancer Research*, **2003**, 9, 1161-70	12.9	79
18	Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. *International Journal of Molecular Medicine*, **2002**, 10, 385	4.4	
17	The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. *Cancer Biology and Therapy*, **2002**, 1, 256-62	4.6	22
16	Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. *Journal of Biological Chemistry*, **2002**, 277, 30469-76	5.4	49
15	Raf-Induced Cell Cycle Progression in Human TF-1 Hematopoietic Cells. *Cell Cycle*, **2002**, 1, 218-224	4.7	21
14	Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies. *Expert Opinion on Therapeutic Targets*, **2002**, 6, 659-78	6.4	25
13	Raf-induced cell cycle progression in human TF-1 hematopoietic cells. *Cell Cycle*, **2002**, 1, 220-6	4.7	11

12	P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. *Oncogene*, **2001**, 20, 4354-64	9.2	36
11	Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. *Advances in Enzyme Regulation*, **2001**, 41, 289-323		18
10	A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. *Oncogene*, **2000**, 19, 526-36	9.2	73
9	The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors **2000**, 88, 229-79		77
8	Calcium-induced ERK activation in human T lymphocytes occurs via p56(Lck) and CaM-kinase. *Molecular Immunology*, **2000**, 37, 675-83	4.3	53
7	Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. *Advances in Enzyme Regulation*, **2000**, 40, 305-37		19
6	Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. *Journal of Immunological Methods*, **1993**, 157, 233-40	2.5	262
5	Structure and expression of the T cell receptor gamma locus in pre-B and early hemopoietic cells. *European Journal of Immunology*, **1989**, 19, 2303-8	6.1	10
4	Transfer of specificity by murine alpha and beta T-cell receptor genes. *Nature*, **1986**, 320, 232-8	50.4	526
3	Transformation of B and non-B cell lines with the 2,4,6,-trinitrophenyl (TNP)-specific immunoglobulin genes. *European Journal of Immunology*, **1985**, 15, 1117-24	6.1	11
2	Activation of nonexpressed endogenous ecotropic murine leukemia virus by transfection of genomic DNA into embryo cells. *Journal of Virology*, **1983**, 45, 950-5	6.6	4
1	Genetic interactions in induction of endogenous murine leukemia virus from low leukemic mice. *Cell*, **1982**, 28, 881-8	56.2	25